Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118364917> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2118364917 endingPage "287" @default.
- W2118364917 startingPage "282" @default.
- W2118364917 abstract "Background Melasma is an irregular brown or grayish-brown symmetric facial hypermelanosis, often affecting women, especially those living in areas with intense ultraviolet radiation. Objective Comparison of therapeutic effects of 20% azelaic acid and 4% hydroquinone cream in the treatment of melasma. Methods Twenty-nine women with melasma were recruited. Fifteen patients were treated with 4% hydroquinone cream and 14 patients were treated with azelaic acid cream for 2 months. The cream was applied twice daily. A broad-spectrum sunscreen was used concomitantly by both groups. The Melasma Area Severity Index (MASI) scores were determined prior to treatment and at each follow-up. Results The mean MASI score before treatment was 7.2 ± 3.2 in the hydroquinone group and 7.6 ± 3.5 in the azelaic acid group, with no significant difference between them (t-test, CI 95% = −2.9 to 2.2). One month after treatment, the mean MASI score reached 6.7 ± 3.4 with hydroquinone and 6.3 ± 3.4 with azelaic acid with no significant difference between them (t-test, CI 95% = −2.2 to 3). After 2 months’ treatment, the MASI score was 6.2 ± 3.6 with hydroquinone and 3.8 ± 2.8 with azelaic acid, a significant statistical difference (t-test, CI 95% = 0.03–4.9). Conclusions In conclusion, this study suggests that 20% azelaic acid cream applied twice daily may be more effective than hydroquinone 4% in reducing mild melasma. However, because this was an open trial, it is suggested that further studies involving large groups of patients be conducted to achieve a more conclusive result." @default.
- W2118364917 created "2016-06-24" @default.
- W2118364917 creator A5001807590 @default.
- W2118364917 date "2011-12-01" @default.
- W2118364917 modified "2023-10-13" @default.
- W2118364917 title "Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma" @default.
- W2118364917 cites W142395892 @default.
- W2118364917 cites W1964340452 @default.
- W2118364917 cites W1964551359 @default.
- W2118364917 cites W1968055097 @default.
- W2118364917 cites W1981757494 @default.
- W2118364917 cites W1985071176 @default.
- W2118364917 cites W1998825789 @default.
- W2118364917 cites W2002085398 @default.
- W2118364917 cites W2011294444 @default.
- W2118364917 cites W2035196124 @default.
- W2118364917 cites W2044189724 @default.
- W2118364917 cites W2046680037 @default.
- W2118364917 cites W2049853929 @default.
- W2118364917 cites W2056980507 @default.
- W2118364917 cites W2145854342 @default.
- W2118364917 cites W2146652970 @default.
- W2118364917 cites W2151149038 @default.
- W2118364917 cites W2159446813 @default.
- W2118364917 doi "https://doi.org/10.1111/j.1473-2165.2011.00580.x" @default.
- W2118364917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22151936" @default.
- W2118364917 hasPublicationYear "2011" @default.
- W2118364917 type Work @default.
- W2118364917 sameAs 2118364917 @default.
- W2118364917 citedByCount "62" @default.
- W2118364917 countsByYear W21183649172012 @default.
- W2118364917 countsByYear W21183649172013 @default.
- W2118364917 countsByYear W21183649172014 @default.
- W2118364917 countsByYear W21183649172015 @default.
- W2118364917 countsByYear W21183649172016 @default.
- W2118364917 countsByYear W21183649172017 @default.
- W2118364917 countsByYear W21183649172018 @default.
- W2118364917 countsByYear W21183649172019 @default.
- W2118364917 countsByYear W21183649172020 @default.
- W2118364917 countsByYear W21183649172021 @default.
- W2118364917 countsByYear W21183649172022 @default.
- W2118364917 countsByYear W21183649172023 @default.
- W2118364917 crossrefType "journal-article" @default.
- W2118364917 hasAuthorship W2118364917A5001807590 @default.
- W2118364917 hasConcept C16005928 @default.
- W2118364917 hasConcept C178790620 @default.
- W2118364917 hasConcept C185592680 @default.
- W2118364917 hasConcept C2776677263 @default.
- W2118364917 hasConcept C2777550763 @default.
- W2118364917 hasConcept C2777673923 @default.
- W2118364917 hasConcept C2778081122 @default.
- W2118364917 hasConcept C2780285341 @default.
- W2118364917 hasConcept C71924100 @default.
- W2118364917 hasConceptScore W2118364917C16005928 @default.
- W2118364917 hasConceptScore W2118364917C178790620 @default.
- W2118364917 hasConceptScore W2118364917C185592680 @default.
- W2118364917 hasConceptScore W2118364917C2776677263 @default.
- W2118364917 hasConceptScore W2118364917C2777550763 @default.
- W2118364917 hasConceptScore W2118364917C2777673923 @default.
- W2118364917 hasConceptScore W2118364917C2778081122 @default.
- W2118364917 hasConceptScore W2118364917C2780285341 @default.
- W2118364917 hasConceptScore W2118364917C71924100 @default.
- W2118364917 hasIssue "4" @default.
- W2118364917 hasLocation W21183649171 @default.
- W2118364917 hasLocation W21183649172 @default.
- W2118364917 hasOpenAccess W2118364917 @default.
- W2118364917 hasPrimaryLocation W21183649171 @default.
- W2118364917 hasRelatedWork W1999031445 @default.
- W2118364917 hasRelatedWork W2080217405 @default.
- W2118364917 hasRelatedWork W2094101007 @default.
- W2118364917 hasRelatedWork W2094537838 @default.
- W2118364917 hasRelatedWork W2151149038 @default.
- W2118364917 hasRelatedWork W2278132114 @default.
- W2118364917 hasRelatedWork W2435105114 @default.
- W2118364917 hasRelatedWork W2725950267 @default.
- W2118364917 hasRelatedWork W3045615572 @default.
- W2118364917 hasRelatedWork W144840236 @default.
- W2118364917 hasVolume "10" @default.
- W2118364917 isParatext "false" @default.
- W2118364917 isRetracted "false" @default.
- W2118364917 magId "2118364917" @default.
- W2118364917 workType "article" @default.